[ET Net News Agency, 8 April 2020] Guotai Junan International lowered its target price
for CSPC Pharmaceutical Group (01093) to HK$22.5 from HK$24.9 and maintained its "buy"
rating.
The research house said CSPC's 2019 results were broadly in line with Guotai Junan's
expectation. Due to the outbreak of COVID-19, medical demand was depressed, and thus the
number of prescriptions dropped in China. As the outbreak was effectively controlled in
China, Guotai Junan expects that CSPC's marketing and R&D will return to normal starting
from 2Q.
Looking ahead to 2020, Guotai Junan believes that the bottom-line growth of CSPC could
still approach nearly 20%, with consideration to the robust growth momentum of its
existing products and a rich and productive pipeline serving as new engines. (KL)
|
|
|
|
|
|
|
|
|
|
Super Quote | Detail Quote | Interactive Chart | Transaction | Related News | Related Securities | Company Information | Dividend Records | Short Sell
01093 CSPC PHARMA
Nominal 
6.180 +0.130 (+2.149%) Research Report
08/04/2020 15:29
Guotai Junan trims CSPC Pharma (01093) to HK$22.5
| Remark: | Real time quote last updated: 24/04/2024 11:20 |
| Real-time basic market prices of Hong Kong securities are provided by HKEx; a Designated Website authorized by the HKEx Group to provide the Service |